Author
Listed:
- Hebah A. Sindi
(Imperial College London
Department of Biology)
- Giusy Russomanno
(Imperial College London)
- Sandro Satta
(Imperial College London)
- Vahitha B. Abdul-Salam
(Imperial College London)
- Kyeong Beom Jo
(Imperial College London)
- Basma Qazi-Chaudhry
(King’s College London UK)
- Alexander J. Ainscough
(Imperial College London)
- Robert Szulcek
(Amsterdam Cardiovascular Sciences (ACS))
- Harm Bogaard
(Amsterdam Cardiovascular Sciences (ACS))
- Claire C. Morgan
(Imperial College London)
- Soni S. Pullamsetti
(Member of the German Center for Lung Research (DZL)
Justus Liebig University)
- Mai M. Alzaydi
(Imperial College London
King Abdulaziz City for Science and Technology (KACST))
- Christopher J. Rhodes
(Imperial College London)
- Roberto Piva
(University of Turin)
- Christina A. Eichstaedt
(German Center for Lung Research (DZL)
Heidelberg University)
- Ekkehard Grünig
(German Center for Lung Research (DZL))
- Martin R. Wilkins
(Imperial College London)
- Beata Wojciak-Stothard
(Imperial College London)
Abstract
Pulmonary arterial hypertension (PAH) is a severe disorder of lung vasculature that causes right heart failure. Homoeostatic effects of flow-activated transcription factor Krüppel-like factor 2 (KLF2) are compromised in PAH. Here, we show that KLF2-induced exosomal microRNAs, miR-181a-5p and miR-324-5p act together to attenuate pulmonary vascular remodelling and that their actions are mediated by Notch4 and ETS1 and other key regulators of vascular homoeostasis. Expressions of KLF2, miR-181a-5p and miR-324-5p are reduced, while levels of their target genes are elevated in pre-clinical PAH, idiopathic PAH and heritable PAH with missense p.H288Y KLF2 mutation. Therapeutic supplementation of miR-181a-5p and miR-324-5p reduces proliferative and angiogenic responses in patient-derived cells and attenuates disease progression in PAH mice. This study shows that reduced KLF2 signalling is a common feature of human PAH and highlights the potential therapeutic role of KLF2-regulated exosomal miRNAs in PAH and other diseases associated with vascular remodelling.
Suggested Citation
Hebah A. Sindi & Giusy Russomanno & Sandro Satta & Vahitha B. Abdul-Salam & Kyeong Beom Jo & Basma Qazi-Chaudhry & Alexander J. Ainscough & Robert Szulcek & Harm Bogaard & Claire C. Morgan & Soni S. P, 2020.
"Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension,"
Nature Communications, Nature, vol. 11(1), pages 1-17, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-14966-x
DOI: 10.1038/s41467-020-14966-x
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-14966-x. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.